Diabetes mellitus is a disease in which the body loses its ability to provide tight regulation and maintain a dynamic interaction between the tissue sensitivity and insulin secretion by β cells. The impact of this dysfunctional mechanism is uncontrolled blood glucose levels that lead to hyperglycemia condition. Highly reactive free radicals have a strong involvement in the pathogenesis of diabetes mellitus, where one of its forming process may be triggered by hyperglycemia condition. Patients with diabetes mellitus itself vulnerable to endothelial dysfunction, which is caused by a decrease in circulating endothelial progenitor cells, and also a decrease in chemokines which play a role in affecting the activities of these cells. Hyperglycemia condition and free radical activity is a major cause of these endothelial progenitor cells dysfunction.The purpose of this study was to determine the role of VipAlbumin®, a supplement derived from Channa striatus albumin extracts in inhibiting the action of free radicals that are formed due to hyperglycemia condition, which can affect the increase in endothelial progenitor cells relative amount. This study used BALB/C mice that induced to undergo diabetes mellitus through streptozotocin injection intraperitoneally at 5-day old. Mice who have reached 4 week old and positive to diabetes mellitus (blood glucose levels > 200 mg.dl -1 ) will be administered with VipAlbumin® orally for 14 days. VipAlbumin® dosage was divided into 4 groups: positive control (without VipAlbumin®); 1 st dose (0.01664 mg.gr -1 BW); 2 nd dose (0.416 mg.gr -1 BW); 3 rd dose (10.4 mg.gr -1 BW). The last step was flow cytometric analysis to determine the development of endothelial progenitor cells relative amount, which isolated from bone marrow. The variables measured in this study were the relative amount of CD34 + and SDF-1. Based to flow cytometric analysis, mice with VipAlbumin® administration did not show any significant improvement in CD34 relative amount when compared to the positive control. Relative amount of Chemokine SDF-1 itself, although only occur at the 3 rd dose of VipAlbumin® treatment, has increased and significantly different from the positive control.
Diabetes mellitus is a metabolic disease that is caused either by the decrease of insulin secretion from pancreatic β cells or the insensitivity of target cells against insulin. High glucose levels (hyperglycemia condition) can trigger the formation of free radicals, the main cause of diabetes micro and macrovascular complications. The formation of free radicals and AGE (advanced glycation end-products) is assumed to became the key factor in the decline of granulocyte cell production as well as the disruption of these cells functional activity. The purpose of this research was to determine the role of VipAlbumin ® in inhibiting the adverse effects of increased blood glucose levels, which highly influence the production of granulocyte. This study was divided into in vitro and in vivo stage. BALB/C mice were used as experimental animals at in vivo stage and induced to undergo diabetes through 100 mg/kg BW streptozotocin (STZ) injection at the age of 5 days. VipAlbumin® administered orally for 14 days, which began when mice reached the age of 14 weeks. The administration of VipAlbumin® divided into 3 doses i.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.